X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5925) 5925
Publication (298) 298
Newsletter (267) 267
Book Review (51) 51
Newspaper Article (44) 44
Magazine Article (19) 19
Dissertation (10) 10
Book Chapter (5) 5
Data Set (3) 3
Trade Publication Article (3) 3
Report (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4424) 4424
omeprazole (3697) 3697
male (3526) 3526
female (2847) 2847
adult (2302) 2302
middle aged (2202) 2202
omeprazole - administration & dosage (2194) 2194
gastroenterology & hepatology (1753) 1753
pharmacology & pharmacy (1558) 1558
proton pump inhibitors (1539) 1539
index medicus (1446) 1446
aged (1431) 1431
anti-ulcer agents - administration & dosage (1428) 1428
omeprazole - therapeutic use (1278) 1278
helicobacter infections - drug therapy (1210) 1210
drug therapy, combination (1090) 1090
lansoprazole (1086) 1086
treatment outcome (1073) 1073
2-pyridinylmethylsulfinylbenzimidazoles (1030) 1030
anti-ulcer agents - therapeutic use (994) 994
helicobacter pylori (990) 990
omeprazole - analogs & derivatives (973) 973
animals (885) 885
omeprazole - pharmacology (797) 797
drug administration schedule (789) 789
amoxicillin - administration & dosage (648) 648
administration, oral (634) 634
dose-response relationship, drug (627) 627
rats (596) 596
time factors (575) 575
double-blind method (571) 571
anti-bacterial agents - administration & dosage (567) 567
pharmacokinetics (559) 559
omeprazole - adverse effects (553) 553
gastroesophageal reflux - drug therapy (550) 550
clarithromycin - administration & dosage (544) 544
prospective studies (544) 544
adolescent (539) 539
ranitidine (521) 521
therapy (499) 499
helicobacter pylori - drug effects (493) 493
proton pump inhibitors - administration & dosage (487) 487
drug interactions (477) 477
hydrogen-ion concentration (462) 462
rabeprazole (457) 457
anti-ulcer agents - pharmacology (455) 455
proton pump inhibitor (450) 450
infection (445) 445
duodenal ulcer - drug therapy (430) 430
aged, 80 and over (429) 429
pantoprazole (428) 428
omeprazole - pharmacokinetics (410) 410
cross-over studies (404) 404
gastroesophageal reflux (387) 387
eradication (381) 381
amoxicillin (373) 373
medicine, general & internal (358) 358
risk factors (355) 355
benzimidazoles - administration & dosage (353) 353
anti-bacterial agents - therapeutic use (351) 351
metronidazole - administration & dosage (347) 347
stomach ulcer - drug therapy (346) 346
follow-up studies (345) 345
clarithromycin (342) 342
dosage and administration (341) 341
research (339) 339
anti-ulcer agents - adverse effects (334) 334
peptic ulcer - drug therapy (328) 328
gastric mucosa - drug effects (327) 327
gastric acid - secretion (326) 326
recurrence (324) 324
esomeprazole (321) 321
gastric acid - metabolism (321) 321
duodenal-ulcer (315) 315
disease (314) 314
efficacy (311) 311
enzyme inhibitors - administration & dosage (310) 310
drug therapy (309) 309
proton pump inhibitors - therapeutic use (309) 309
medicine & public health (308) 308
care and treatment (299) 299
double-blind (295) 295
young adult (294) 294
amoxicillin - therapeutic use (290) 290
proton pump inhibitors - adverse effects (286) 286
gastric acidity determination (280) 280
triple therapy (275) 275
management (271) 271
gastrins - blood (262) 262
area under curve (261) 261
intragastric ph (260) 260
ranitidine - administration & dosage (257) 257
drugs (255) 255
clarithromycin - therapeutic use (254) 254
gastroesophageal-reflux disease (253) 253
cytochrome p-450 cyp2c19 (251) 251
metabolism (246) 246
analysis (245) 245
ulcers (245) 245
helicobacter infections - complications (242) 242
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5690) 5690
German (129) 129
Japanese (108) 108
Spanish (93) 93
Russian (84) 84
French (44) 44
Chinese (26) 26
Italian (19) 19
Korean (15) 15
Swedish (14) 14
Norwegian (8) 8
Portuguese (8) 8
Ukrainian (6) 6
Danish (5) 5
Hungarian (5) 5
Polish (5) 5
Czech (4) 4
Croatian (3) 3
Bulgarian (2) 2
Dutch (2) 2
Bosnian (1) 1
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2014, Volume 96, Issue 3, pp. 349 - 359
The suitability of the capillary dried blood spot (DBS) sampling method was assessed for simultaneous phenotyping of cytochrome P450 (CYP) enzymes and... 
P4502B6 ACTIVITY | VORICONAZOLE | LC-MS/MS | SINGLE-POINT | ORAL MIDAZOLAM | VOLUNTEERS | IN-VIVO | PHARMACOLOGY & PHARMACY | DRUG-METABOLIZING-ENZYMES | KAROLINSKA COCKTAIL | BUPROPION HYDROXYLATION | Predictive Value of Tests | Pharmaceutical Preparations - blood | Caffeine - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Dried Blood Spot Testing | Humans | Omeprazole - blood | Bupropion - blood | Midazolam - administration & dosage | Substrate Specificity | Male | Chromatography, High Pressure Liquid | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Coffee | Terfenadine - administration & dosage | Caffeine - pharmacokinetics | Feasibility Studies | Enzyme Inhibitors - administration & dosage | Young Adult | Chromatography, Reverse-Phase | Tandem Mass Spectrometry | Capsules | Spectrometry, Mass, Electrospray Ionization | Flurbiprofen - administration & dosage | Adult | Dextromethorphan - pharmacokinetics | Terfenadine - blood | ATP-Binding Cassette, Sub-Family B, Member 1 - blood | Pharmaceutical Preparations - administration & dosage | Terfenadine - pharmacokinetics | Bupropion - pharmacokinetics | Flurbiprofen - pharmacokinetics | Cytochrome P-450 Enzyme System - blood | Administration, Oral | Isoenzymes | Caffeine - blood | Omeprazole - administration & dosage | Terfenadine - analogs & derivatives | Omeprazole - pharmacokinetics | Carbonated Beverages | Midazolam - pharmacokinetics | Bupropion - administration & dosage | Dextromethorphan - blood | Flurbiprofen - blood | Phenotype | Pilot Projects | Midazolam - blood | Dextromethorphan - administration & dosage | Usage | Glycoproteins | Liquid chromatography | Research | Pharmacokinetics | Cytochrome P-450 | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Surgery, ISSN 0003-4932, 08/2013, Volume 258, Issue 2, pp. 262 - 269
OBJECTIVE:We conducted a pharmacokinetic (PK) study and a pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated... 
furosemide | oral cocktail | CYP3A | gastric bypass | drug metabolism | SURGERY | FATTY LIVER-DISEASE | WEIGHT-LOSS | TRENDS | P-GLYCOPROTEIN | OBESITY | INTESTINAL ADAPTATION | BARIATRIC SURGERY | ABSORPTION | HEPATIC STEATOSIS | Gastric Bypass | Diuretics - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Middle Aged | Tolbutamide - urine | Male | Caffeine - pharmacokinetics | Midazolam - urine | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Diuretics - urine | Diuretics - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Furosemide - pharmacokinetics | Omeprazole - administration & dosage | Excitatory Amino Acid Antagonists - administration & dosage | Hypoglycemic Agents - urine | Omeprazole - urine | Central Nervous System Stimulants - pharmacokinetics | Midazolam - blood | Dextromethorphan - urine | Adolescent | GABA Modulators - urine | Central Nervous System Stimulants - urine | Dextromethorphan - administration & dosage | Furosemide - administration & dosage | Tolbutamide - administration & dosage | Tolbutamide - pharmacokinetics | Caffeine - administration & dosage | Omeprazole - blood | GABA Modulators - pharmacokinetics | Midazolam - administration & dosage | Anti-Ulcer Agents - blood | Chromatography, High Pressure Liquid | Case-Control Studies | Excitatory Amino Acid Antagonists - urine | Hypoglycemic Agents - blood | Tandem Mass Spectrometry | Biotransformation | Adult | Female | Dextromethorphan - pharmacokinetics | Furosemide - urine | Caffeine - urine | Caffeine - blood | GABA Modulators - administration & dosage | GABA Modulators - blood | Omeprazole - pharmacokinetics | Anti-Ulcer Agents - urine | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Dextromethorphan - blood | Excitatory Amino Acid Antagonists - blood | Tolbutamide - blood | Aged | Central Nervous System Stimulants - blood | Pharmacokinetics | Central Nervous System Stimulants - administration & dosage
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9769, pp. 905 - 913
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2009, Volume 68, Issue 6, pp. 928 - 935
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Numerous cocktails using concurrent administration of several cytochrome P450 (CYP) isoform-selective probe drugs... 
in vivo drug-drug interaction | cocktail | CYP | Cocktail | In vivo drug-drug interaction | DRUG | CAFFEINE | COMBINED PHENOTYPIC ASSESSMENT | METOPROLOL | OMEPRAZOLE TREATMENT | XANTHINE-OXIDASE | METABOLISM | ENZYMES | IN-VIVO | N-ACETYLTRANSFERASE-2 | PHARMACOLOGY & PHARMACY | Anti-Anxiety Agents - administration & dosage | Caffeine - administration & dosage | Anticoagulants - administration & dosage | Area Under Curve | Humans | Midazolam - administration & dosage | Cytochrome P-450 CYP1A2 - administration & dosage | Male | Metabolic Clearance Rate | Warfarin - administration & dosage | Caffeine - pharmacokinetics | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Anti-Anxiety Agents - pharmacokinetics | Drug Interactions | Adult | Drug Therapy, Combination | Administration, Oral | Omeprazole - administration & dosage | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Central Nervous System Stimulants - pharmacokinetics | Anticoagulants - pharmacokinetics | Central Nervous System Stimulants - administration & dosage | Drug Combinations | Cytochrome P-450 CYP1A2 - pharmacokinetics | Omeprazole | Warfarin | Analysis | Drug interactions | Cytochrome P-450 | Physiological aspects | Liquid chromatography | Mass spectrometry | Caffeine | Drug Metabolism | in vivo drug–drug interaction
Journal Article
Journal of Nephrology, ISSN 1121-8428, 12/2014, Volume 27, Issue 6, pp. 659 - 666
The novel iron-based phosphate binder sucroferric oxyhydroxide is being investigated for the treatment of hyperphosphatemia. Patients with chronic kidney... 
Nephrology | Phase I | Medicine & Public Health | Urology/Andrology | Hyperphosphatemia | Chronic kidney disease | Pharmacokinetics | Sucroferric oxyhydroxide | MORTALITY | PHOSPHORUS | PHOSPHATE BINDER | BIOAVAILABILITY | INDIVIDUALS | DIALYSIS PATIENTS | PA21 | CALCIUM | UROLOGY & NEPHROLOGY | HEMODIALYSIS | CHRONIC KIDNEY-DISEASE | Digoxin - adverse effects | Diuretics - pharmacokinetics | Chelating Agents - administration & dosage | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Warfarin - administration & dosage | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Cardiotonic Agents - adverse effects | Diuretics - blood | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Risk Assessment | Furosemide - pharmacokinetics | Cardiotonic Agents - pharmacokinetics | Omeprazole - administration & dosage | Sucrose - adverse effects | Anticoagulants - adverse effects | Anticoagulants - blood | Cardiotonic Agents - administration & dosage | Models, Biological | Ferric Compounds - adverse effects | Losartan - administration & dosage | Diuretics - adverse effects | Furosemide - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Anticoagulants - administration & dosage | Area Under Curve | Losartan - blood | Omeprazole - blood | Warfarin - adverse effects | Ferric Compounds - administration & dosage | Healthy Volunteers | Furosemide - adverse effects | Adult | Female | Proton Pump Inhibitors - blood | Digoxin - blood | Losartan - pharmacokinetics | Chelating Agents - adverse effects | Furosemide - blood | Sucrose - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Models, Statistical | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Proton Pump Inhibitors - pharmacokinetics | Digoxin - administration & dosage | Cardiotonic Agents - blood | Warfarin - blood | Losartan - adverse effects | Anticoagulants - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - blood | Drug Combinations | Original
Journal Article
Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 2/2015, Volume 60, Issue 2, pp. 458 - 464
Helicobacter pylori eradication is a challenge in penicillin allergy.To assess the efficacy and safety of first-line and rescue treatments in patients allergic... 
Biochemistry, general | Levofloxacin | Allergy | Quinolone | Oncology | Eradication | Allergic | Transplant Surgery | Medicine & Public Health | Helicobacter pylori | Hepatology | Gastroenterology | Penicillin | Bismuth | CLARITHROMYCIN | ANTIBIOTIC-RESISTANCE | QUADRUPLE THERAPY | PROTON PUMP INHIBITOR | TRIPLE THERAPY | INFECTION | METRONIDAZOLE | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT FAILURE | Predictive Value of Tests | Bismuth - administration & dosage | Prospective Studies | Humans | Middle Aged | Salvage Therapy | Helicobacter pylori - drug effects | Male | Rifabutin - administration & dosage | Proton Pump Inhibitors - administration & dosage | Time Factors | Antacids - adverse effects | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Penicillins - adverse effects | Female | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Drug Therapy, Combination | Levofloxacin - administration & dosage | Drug Hypersensitivity - etiology | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Metronidazole - administration & dosage | Omeprazole - administration & dosage | Breath Tests | Treatment Outcome | Spain | Medication Adherence | Helicobacter pylori - isolation & purification | Antacids - administration & dosage | Anti-Bacterial Agents - administration & dosage | Tetracycline - administration & dosage | Helicobacter Infections - microbiology | Urea | Antibacterial agents | Allergic reaction
Journal Article
Chirality, ISSN 0899-0042, 12/2018, Volume 30, Issue 12, pp. 1277 - 1286
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 3, p. e9836
Antibiotic administration is the standard treatment for the bacterium Helicobacter pylori, the main causative agent of peptic ulcer disease and gastric cancer.... 
CLARITHROMYCIN | RESISTANCE GENES | INTESTINAL MICROFLORA | HELICOBACTER-PYLORI INFECTION | FLORA | PERSISTENCE | BIOLOGY | POPULATIONS | MACROLIDE RESISTANCE | GRADIENT GEL-ELECTROPHORESIS | 16S RIBOSOMAL-RNA | Oligonucleotides - genetics | Dyspepsia - drug therapy | Humans | Metronidazole - administration & dosage | Omeprazole - administration & dosage | Gastrointestinal Tract - microbiology | Gastrointestinal Tract - drug effects | Drug Resistance, Microbial - genetics | Phylogeny | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Polymorphism, Restriction Fragment Length | Time Factors | Clarithromycin - administration & dosage | RNA, Ribosomal, 16S - genetics | Feces | Pharynx - drug effects | Pharynx - microbiology | Drug resistance in microorganisms | Care and treatment | Antibiotics | Microbiota (Symbiotic organisms) | RNA | Analysis | Peptic ulcer | Stomach cancer | Antiulcer drugs | Short term | Microbial activity | Clarithromycin | rRNA 16S | Microbiology | Genes | Colorectal cancer | Biology | Drug resistance | Gene polymorphism | Data bases | Microorganisms | Helicobacter pylori | Intestine | Antibiotic resistance | Phylogenetics | Bacteria | Gastric cancer | Deoxyribonucleic acid--DNA | Pharynx | Disease control | Bacteriology | Polymerase chain reaction | Infectious diseases | Restriction fragment length polymorphism | Metronidazole | Cancer | Long-term effects | Polymorphism | ULCERS | ANTIBIOTICS | 58 | DISEASES | THERAPY | NEOPLASMS | GENES | FECES | COMMUNITIES | METRONIDAZOLE | 54 | Microbial/genetics | Ribosomal | Pharynx/drug effects/microbiology | Restriction Fragment Length | Gastrointestinal Tract/drug effects/microbiology | Clarithromycin/administration & dosage | Omeprazole/administration & dosage | Metronidazole/administration & dosage | Oligonucleotides/genetics | Naturvetenskap | Natural Sciences | Dyspepsia/drug therapy | 16S/genetics | Anti-Bacterial Agents/therapeutic use | Drug Resistance | Deoxyribonucleic acid | DNA
Journal Article